Polyplus, a company that provides upstream solutions for biologic and cell therapies from research to commercialization, has expanded its transgene plasmid engineering services for viral vector manufacturing. The expanded plasmid services can be used as a stand alone or as a complement to PEIproR and FectoVIR-AAVR reagents and kits for next generation viral vector and gene therapy manufacturing.
According to Mario Philips, Polyplus' CEO, integration efforts focused on providing a wider range of solutions to customers following the acquisition of e-Zyvec in early 2022, eliminating the need for standard backbones that contain unidentified DNA sequences. Plasmids can be engineered in two weeks through the Polyplus online plasmid engineering tool.
According to Philips, we are one of the few businesses in the market that can provide a fully customizable plasmid engineering service. This cutting-edge and rapid plasmid engineering service will assist the viral vector industry in optimizing process profitability for advanced therapy manufacturing and enabling customers to meet their time-to-market objectives.